Trial
NCT02535247
Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Fox Chase Cancer Center
Collaborators
Merck Sharp & Dohme LLC
Condition
Lymphoma, T-Cell, Peripheral
Intervention
MK-3475
Why stopped
Merck no longer providing drug for study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-07-08